This is a randomized, double-blind, multicenter Phase IIIb study comparing remibrutinib tablets with dupilumab injections in adults with chronic spontaneous urticaria (CSU) that is not well controlled by second-generation H1-antihistamines. Participants will receive either remibrutinib or dupilumab for 12 weeks, alongside their usual antihistamine. The goal is to see which treatment works faster and better at reducing symptoms like hives and itching. If remibrutinib is not yet available commercially after the study, participants may continue taking it in an optional extension phase.

This study is a double‑blind, placebo‑controlled research study to evaluate the safety and effectiveness of a skin patch treatment for peanut allergy in children ages 1 to 3. The patch delivers a very small amount of peanut protein through the skin and is designed to help the immune system become less sensitive to peanuts over time.

Participation in the study will last approximately 34 weeks. Participation is voluntary, and participants may withdraw at any time.

The purpose of this study is to evaluate the efficacy and safety of ibuzatrelvir with and without remdesivir compared with remdesivir alone for the treatment of symptomatic COVID-19 in adult participants who are severely immunocompromised. This study is being done to learn how the study drug, called ibuzatrelvir, works in treating people with COVID-19 who have a severely compromised immune system. Ibuzatrelvir stops the virus that causes COVID-19 from multiplying in cells and spreading around the body. It may help people to get better and stay out of the hospital.

This is a double‑blind, placebo‑controlled study, meaning participants may receive either the study medication, Ibuzatrelvir, or a placebo. The goal is to see whether the study medication helps participants recover faster and lowers the risk of hospitalization or severe illness. Participant safety is closely monitored.

You can change your mind and stop taking part in the study at any time and for any reason. You will not lose any benefits or care you would normally receive.

If you would like more information about this study, please contact the study team.